48 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Antitumor agents. 3. Synthesis and biological activity of 4 beta-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents.
Taiho Pharmaceutical
1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors.
Taiho Pharmaceutical
Discovery of highly potent human deoxyuridine triphosphatase inhibitors based on the conformation restriction strategy.
Taiho Pharmaceutical
Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors.
Taiho Pharmaceutical
Synthesis and discovery of N-carbonylpyrrolidine- or N-sulfonylpyrrolidine-containing uracil derivatives as potent human deoxyuridine triphosphatase inhibitors.
Taiho Pharmaceutical
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Taiho Pharmaceutical
Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.
Taiho Pharmaceutical
Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
Taiho Pharmaceutical
Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
Incyte
Azetidine derivative, preparation method therefor, and use thereof
Sichuan Kelun-Biotech Biopharmaceutical
Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
Boehringer Ingelheim International
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.
A*Star
3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
Arena Pharmaceuticals
Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
Rugen Holdings (Cayman)
Synthesis and carbonic anhydrase isoenzymes I and II inhibitory effects of novel benzylamine derivatives.
Ataturk University
Inhibitors of rho associated protein kinases (ROCK) and methods of use
H. Lee Moffin Cancer Center and Research Institute
Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase
The University of Denver and Regis University
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.
Suven Life Sciences
Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.
Duquesne University
Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
Dartmouth College
Synthesis of 6-chloro-2-Aryl-1H-imidazo[4,5-b]pyridine derivatives: Antidiabetic, antioxidant, ß-glucuronidase inhibiton and their molecular docking studies.
Universiti Teknologi Mara (Uitm), Puncak Alam Campus
Synthesis and tyrosinase inhibition activity of trans-stilbene derivatives.
Indian Institute of Integrative Medicine
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
University of Arkansas
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
Centre De Recherches De Croissy
RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.
Roche Bioscience
Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
Abbott Laboratories
Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand.
Department of Veterans Affairs Medical Center
Competition of leukotrienes and ICI-198,615 for [3H]LTD4 binding sites in guinea pig lung membranes suggests the involvement of two LTD4 receptor subtypes.
Pfizer